Copy For Citation
Kalincik T., Havrdova E. K. , Horakova D., Izquierdo G., Prat A., Girard M., ...More
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol.90, no.4, pp.458-468, 2019 (SCI-Expanded)
Objective Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed.